Blocking angiotensin II receptors with losartan reduces cardiovascular events and strokeBMJ 2002; 324 doi: https://doi.org/10.1136/bmj.324.7340.756/d (Published 30 March 2002) Cite this as: BMJ 2002;324:756
- Susan Mayor
Blocking angiotensin II receptors with losartan significantly reduces the risk of cardiovascular disease and death, as well as reducing the risk of stroke by a quarter, compared with β blockade with atenolol, in patients with hypertension and left ventricular hypertrophy.
These were the key findings from the first major trial to show a difference in cardiovascular outcomes between antihypertensives with different mechanisms of action. The trial's results were reported last week at the annual scientific meeting of the American College of Cardiology in Atlanta.
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial